calciol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases serum prostate-specific antigen
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Compared to patients of group-A, those of group-B developed a significantly lower level of PSA at the end of treatment period (0.16 ± 0.03 ng/mL vs. 0.27 ± 0.08 ng/mL, p 0.043, OR 1.9, 95% CI 1.2-6.8).”
Quoted verbatim from Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study.. - Study
- RCT
- Population
- Naive men with benign prostatic hyperplasia and moderate/severe symptoms; tamsulosin given to both arms as background, cholecalciferol added in one arm; end of 2-year treatment period
Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study.2019PMID:30361957Permalink
Keep reading
- Everything the graph holds on calciol
- Every compound studied against Serum prostate-specific antigen
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5KCFRS7E8TA2AEY9YMS02W2